1. -The symptoms of asthma are caused in part by the binding of cytokines IL-4 and IL-13 to their respective receptors.
-Dupilumab is able to bind to the IL4-receptor chain alpha, which is found in both of the aforementioned receptors.
-The binding action of Dupilumab to these protein chain alters the binding site of these receptors, resulting in the cytokines being unable to bind to their receptors, and thus the introduction of these monoclonal antibodies into the body may lessen the symptoms of asthma.
2. Monoclonal antibodies against the IL-4 protein chain alpha may be produced by injecting these proteins into a non human organism, such as mice. In doing so, the protein fragments would be recognised as non self in the organism they were introduced into. Thus, specific antibodies would be produced against it in large numbers. These antibodies could then be extracted and then be refined for human use.
I have no idea how relevant/accurate any of this is, but I tried to answer this as I would a VCAA question, I have found the answer to their questions are usually simple and relatively uncomplicated, which is what I tried to do here 
1. Your answer to number one is pretty spot on the money. Don't dismiss the possibility that the antibodies could be acting as a competitive inhibitor, however! Antibodies are really huge molecules and are actually really good competitive inhibitors because they cover so much surface

Really good answer though, just adding in the extra info!
2. Your answer to number two is exactly what I was looking for. This does not describe the entire process of making monoclonal antibodies (of course it doesn't!) but it's exactly what you'd be expected to know in VCE and also shows a good understanding of the concept of self vs non-self. Really well done
Not sure any of this actually says anything, but yeah 
1. Dupilumab acts as a competitive inhibitor to the cytokines IL-4 and IL-3, binding to the IL-4 and IL-3 receptors. Thus, the binding of these cytokines is decreased and therefore the effects of asthma are also decreased.
2. Mice are injected with the antigens and produce antibodies against it. The plasma cells are taken from the mice and mixed with tumour cells to create hybridomas. The hybridoma cells that make the desired antibody are then cultured to produce large amounts of it.
1. That's pretty spot on the money. Asthma is an allergic disorder. IL-4 in particular plays a really key role in the allergic response; so by blocking it, asthma can't really develop
2. I suspect Google may have helped a little with this one :p Funnily enough though, this isn't actually how dupilumab is made—it's a bit more complicated than the old way they made murine antibodies!
Ok here's another shot
1. Dupilumab has complementary binding sites to IL-4, which is a cytokine, presumably histamine. As a result of binding to this cytokine, the antibody inhibits its function by agglutination of IL-4 hence preventing circulation of the cytokine around the body. As a result, allergic side effects like inflammation and swelling is decreased.
2. Genes for Production of human antibodies are inserted into another animal via a recombinant plasmid. The animal then produces this monoclonal antibody and the antibodies are collected for use.
Not sure if half of what I said was relevant, Lol
1. You're right in pursuing the theme of the antibody being complementary to something and thereby inhibiting it, but once again you need to be really careful about how you read the question. The question stated that dupilumab binds the IL-4 receptor chain alpha, which is a shared component of the IL-4 and IL-13 receptors. Dupilumab doesn't bind IL-4 at all, it binds its receptor. Binding its receptor essentially has the same effect though; it prevents IL-4 from signalling to cells
2. A good answer and a completely reasonable one in these circumstances. What I was trying to suggest was that you could inoculate a mouse (this is just a wanky way of saying inject) with IL-4 receptor chain alpha and—because it's a human protein and not a mouse protein—the mouse will produce an immune response against it. Specifically, the mouse will produce antibodies specific to the IL-4 receptor chain alpha.
Your idea about making recombinant antibodies is not a bad one though. To get the specificity to the IL-4 receptor chain alpha, you do need to do as I described above; however, after this what we tend to do now is extract the genes producing antibodies from the B-cells specific to this protein and express these in bacteria as you described. By doing this we can actually fiddle with the genes and take out some mousy bits and replace them with humany bits (so that we don't have an immune response to the antibody!).
FEEDBACK TO EVERYONE
Really pleased with all of your ideas here guys! As I said, this question was meant to be harder than you would cop in a VCAA exam. You shouldn't feel dismayed if you didn't manage to answer it; all of your ideas were valid and showed that you think really well.
Dupilumab is actually a fairly cool drug. It has really improved treatment of asthma for a small section of asthmatics who have really severe, intractable asthma. In these people, standard treatments for asthma fail to do very much for them, so I'm sure you can appreciate how much it means to them to have a treatment that actually controls their asthma well
PS: monoclonal antibodies will be on the new course!